Zentek Ltd. announced the completion of the first in vivo tests of its lead candidate countermeasure for seasonal influenza (H1N1). This milestone was achieved as part of the Innovative Solutions Canada Testing Stream.
The countermeasure was developed using the company's Multivalent Aptamer Technology, showcasing progress in its pharmaceutical product development.
The successful completion of these initial in vivo tests represents a significant step forward in the development of a potential therapeutic solution for influenza.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.